MK-677 vs Ipamorelin
MK-677 (Ibutamoren) and Ipamorelin are both growth hormone secretagogues (GHS) that stimulate GH release via the ghrelin receptor (GHS-R1a). Their key practical difference is route of administration: MK-677 is orally bioavailable, while Ipamorelin requires injection. This makes them fundamentally different research tools despite sharing a receptor target.
MK-677 also has a much longer half-life (~24 hours vs ~2 hours), which means it provides sustained GH and IGF-1 elevation rather than the acute GH pulses produced by Ipamorelin. This distinction significantly impacts their research applications.
Similarities
- =Both are growth hormone secretagogues activating the ghrelin receptor (GHS-R1a)
- =Both stimulate endogenous GH release from the pituitary
- =Both increase IGF-1 levels in published research
- =Both preserve the pulsatile pattern of GH secretion
- =Both are non-peptide (MK-677) and peptide (Ipamorelin) ghrelin mimetics
- =Both are available from research vendors
Key Differences
| Aspect | MK-677 | Ipamorelin |
|---|---|---|
| Administration | Oral (capsule or liquid) — orally bioavailable | Subcutaneous injection — not orally bioavailable |
| Half-Life | ~24 hours — once daily dosing in research | ~2 hours — multiple daily administrations typical |
| GH Release Pattern | Sustained elevation of GH and IGF-1 over 24 hours | Acute GH pulse lasting 2-3 hours per administration |
| Hunger/Appetite | Significant appetite stimulation — a common side effect | Minimal appetite stimulation — most selective GHS |
| Water Retention | Common, especially at higher doses | Minimal |
| Selectivity | Less selective — increases cortisol and prolactin at higher doses | Highly selective — minimal cortisol or prolactin effects |
| Clinical Data | Multiple Phase II trials (Merck) but never FDA-approved | Less formal clinical trial data but extensive research use |
| Chemical Class | Non-peptide small molecule (spiroindoline) | Pentapeptide |
Which to Choose for Your Research
Long-term GH/IGF-1 elevation research
MK-677MK-677's 24-hour half-life provides sustained GH and IGF-1 elevation from once-daily oral dosing. Studies show sustained IGF-1 increases over months of administration.
Clean, selective GH pulse research
IpamorelinIpamorelin is the most selective GHS — it raises GH without significantly affecting cortisol, prolactin, or appetite. Better for studying isolated GH effects.
Oral dosing convenience
MK-677MK-677 is the only orally bioavailable GH secretagogue. For research designs requiring oral administration, it's the only option in this class.
GH peptide stacking research
IpamorelinIpamorelin is commonly combined with CJC-1295 for synergistic GH release. MK-677 is typically studied alone due to its sustained 24-hour activity.
Sleep quality / GH during sleep research
MK-677MK-677 taken before sleep has been shown to increase Stage IV deep sleep duration and GH release during sleep in published studies.
The Verdict
MK-677 and Ipamorelin serve different research needs despite targeting the same receptor. MK-677 is ideal for research requiring sustained, convenient (oral) GH/IGF-1 elevation, but comes with more side effects — appetite stimulation, water retention, and potential cortisol/prolactin increases. Ipamorelin is the cleaner, more selective tool for studying acute GH pulses with minimal off-target effects.
For researchers prioritizing selectivity and combining with GHRH analogs (like CJC-1295), Ipamorelin is preferred. For researchers needing sustained IGF-1 elevation with oral convenience, MK-677 is the better tool.
Frequently Asked Questions
Is MK-677 a SARM?
No. MK-677 (Ibutamoren) is often miscategorized as a SARM because it's sold by some SARM vendors, but it's a growth hormone secretagogue — it works on the ghrelin receptor, not androgen receptors. It has no androgenic activity.
Does MK-677 really increase appetite that much?
Yes, appetite stimulation is one of MK-677's most consistent effects in published studies. It activates the ghrelin receptor, which is the 'hunger hormone' receptor. This is a significant difference from Ipamorelin, which causes minimal appetite changes.
Can MK-677 and Ipamorelin be combined?
They target the same receptor (GHS-R1a), so combining them is generally not studied — they would compete for receptor binding rather than provide additive effects. Ipamorelin is better combined with CJC-1295, which targets a different receptor (GHRH-R).
Why wasn't MK-677 FDA-approved?
Merck conducted multiple Phase II trials but did not pursue FDA approval. The reasons likely include the side effect profile (appetite, water retention, glucose elevation in some studies) and the complexity of GH-related regulatory pathways. It remains a research compound.
MK-677
View full compound page with vendor pricing.
Compare 15 products →Ipamorelin
View full compound page with vendor pricing.
Compare 39 products →More Comparisons
For research reference only. Not medical advice. Not for human consumption. All compounds discussed are research chemicals.